A number of transcription factors such as FOXO3, BCL6, and NFAT have been shown to cause TKI-resistance in mouse models of CML progenitors and in CML cell lines [22–25], but how those transcription pathways and their target genes regulate the death response to TKI has not been elucidated. The gene discussed is BCL6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.